| Description | KGP591, a tubulin polymerization inhibitor with an IC50 of 0.57 µM, effectively induces G2/M arrest, inhibits cell migration, and disrupts microtubule structure and cell morphology in MDA-MB-231 cells. Additionally, it demonstrates antitumor activity in an orthotopic kidney cancer model (RENCA) [1]. |
| In vitro | KGP591在MDA-MB-231细胞中呈现出多方面的生物活性：以100 nM浓度作用72小时，能显著抑制细胞迁移和增殖[1]；同样的浓度，作用30分钟则破坏微管结构[1]；在200 nM浓度和48小时的处理下，观察到G2/M细胞周期停滞现象[1]。 |
| In vivo | KGP591的前体药物KGP618（150 mg/kg，皮下注射，24小时）在RENCA-luc移植的BALB/c小鼠模型中显示出针对肿瘤血管的选择性破坏作用，验证了其作为一种肿瘤选择性血管破坏剂（vascular disrupting agents, VDA）的疗效[1]。 |
| molecular weight | 403.43 |
| Molecular formula | C24H21NO5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |